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http://dx.doi.org/10.1016/j.jds.2013.0Abstract Background/purpose: The human leukocyte antigen (HLA) system, which plays a vi-
tal role in immunity, is the most polymorphic gene complex found in the human genome. This
study investigated HLA-related alleles and haplotypes in Taiwanese patients with oral squa-
mous cell carcinoma (OSCC).
Materials and methods: HLA class I (HLA-A and HLA-B) antigens and class II (HLA-DRB1) alleles
were determined in 105 patients with OSCC and compared with those in 190 healthy controls.
The antigens were measured serologically and the alleles by sequencing-based typing.
Results: Compared with the control group, patients with OSCC had higher frequencies of HLA-
A24, HLA-B54, HLA-DRB1*0405, and HLA-DRB1*1201, while they had lower frequencies of HLA-
B58 and HLA-DRB1*1302. Haplotype frequencies also varied significantly in individuals with
OSCC, with certain haplotypes associated with lymph node metastases or a particular tumor
stage.
Conclusion: These results suggest that HLA genetic factors influence susceptibility to OSCC and
perhaps to lymph node metastasis and tumor progression.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published
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The human leukocyte antigen (HLA) system, located on
chromosome 6 and intimately involved in regulation of the
immune response, is the most polymorphic gene complex
found in the human genome. HLA class IA, B, and C antigens
are expressed by almost all nucleated cells and platelets,
and are recognized by CD8þ cytotoxic T cells. HLA class II
DR, DQ, and DP molecules are expressed by antigen-
presenting cells. Their function is to present exogenous
antigens to CD4þ helper T cells. Obviously, quantitative
changes in HLA expression may alter immune status. How-
ever, the extremely polymorphic nature of this portion of
the genome also results in considerable interindividual
differences. Several HLA types are associated with an
increased risk of various immunologically medicated dis-
eases.1 There is also evidence that the HLA gene complex
may mediate susceptibility to or protection from
malignancies.2,3
Oral cancer ranks sixth in cancer incidence worldwide,
but there are epidemiologic variations between different
geographic regions. It is a leading form of cancer in most
Asian countries and the fourth most common malignancy in
men in Taiwan.4 The frequent use of tobacco, alcohol, and
betel quid among Asians likely accounts in part for regional
variations in disease incidence. However, familial clus-
tering of disease, linkage studies, and molecular findings
also suggest that there may be specific genetic suscepti-
bility among certain individuals. Alterations in immune
function have been detected in patients with oral squamous
cell carcinoma (OSCC),5 along with frequent polymorphous
autoimmune reactions to various tissue antigens.6 The HLA
complex has been implicated in the development of squa-
mous cell carcinoma, particularly in head and neck tumors.
Loss of heterozygosity in the HLA complex may provide
tumor cells with an immune-escape phenotype. HLA class I
expression in OSCC may regulate natural killer cell
activity.7e9
We previously demonstrated an association between
major histocompatibility complex class I chain-related gene
A (MICA) polymorphism and OSCC. Genotyping of the HLA-
A,B locus as well as MICA gene fragments in patients with
OSCC may further improve our understanding of changes in
immune function vis-a`-vis the risk of developing this can-
cer. To the best of our knowledge, little is known about HLA
typing in OSCC in Taiwan or Southeast Asia. Therefore, this
study was designed to investigate the genotype and
haplotype frequencies of HLA-A, HLA-B, and DRB1 in pa-
tients with OSCC.
Materials and methods
Study participants
Between November 2000 and December 2002, we recruited
105 consecutive patients with OSCC from the Oral and
Maxillofacial Department at the Taipei Mackay Memorial
Hospital. The diagnosis was made by histopathologically
examining the biopsy specimens. A total of 105 patients
described themselves ethnically as Min Nan (by a self-
report). The control group included 190 participantsidentified as Min Nan, who visited our clinic for routine
physical examination, minor operations for non-neoplastic
disease, or who had maxillofacial trauma. In both study and
control groups, individuals with autoimmune disorders,
blood diseases, or a history of a previous malignancy were
excluded. The participants were all unrelated to each other.
DNA extraction
Peripheral blood samples were drawn from all the partici-
pants of the study and the control groups. Genomic DNA
was extracted from fresh or frozen peripheral blood leu-
kocytes using the Pharmacia DNA isolation kit (Pharmacia
Biotech, Germany).
HLADRB1 allele typing by sequence-based typing
The group-specific primers used for amplification of exon 2
of DRB1 alleles were modified from those used at the
Diagnostic DNA Laboratory (Utrecht) and Tissue Typing
Laboratory (Maastricht).7 The Utrecht 50 primers were used
for DR1, DR2, DR8/12, and DR7 and the Maastricht primers
for DR3/11/6, DR4, DR9, and DR10. All 50 primers were
located near the 50 end of exon 2 containing an M13 (e21)
sequence at the 50 end for sequencing with the M13
sequencing primer. Because of a polymorphic site at posi-
tion 270, a newly designed 30 primer located at the intron
2eexon 2 junction (GCGCTCACCTCGCCGCTG) was used.
When combined with the group-specific 50 primers, this 30
primer should amplify DRB1 alleles but not DR9. For DR9
amplification, the 30 primer located at position 263e283
(CTCGCCGCTGCACTGTGAAG) was used. Two supplemental
30-end primers, a TG primer (GCTGCACTGTGAAGCTCTCCA),
and a GT primer (GCTGCACTGTGAAGCTCTCAC) located at
position 257e276 were used to separate alleles when initial
group-specific amplification failed to show the two alleles.
The amplification reaction mixture contained 50 ng
genomic DNA, 15 mM TriseHCl (pH 8.0), 50 mM KCl, 1.5 mM
MgCl2, 0.01% gelatin, 0.1% Triton X-100, 0.2 mM of each
deoxyribonucleotide, 5% glycerol, 0.1 mg/mL cresol red,
and 0.25 U of AmpliTaq Gold polymerase (Perkin Elmer,
Foster City, CA, USA).10,11 The polymerase chain reaction
(PCR) was carried out using the GeneAmp PCR system
(Perkin-Elmer Corporation, Foster City, CA, USA). The re-
action mixture was subjected to denaturation at 95C for 10
minutes followed by 32 cycles at 95C for 10 seconds, 62C
for 30 seconds, 72C for 30 seconds, and by a final extension
at 72C for 5 minutes. The PCR products were checked by
2% agarose gel electrophoresis, using 5 mL of reaction vol-
ume, and 1/10 of the diluted PCR products underwent
direct sequencing using a BigDye Primer Cycle Sequencing
Ready Reaction Kit sequence primer (e21M13) (Applied
Biosystems, Foster City, CA, USA). Samples were then
subjected to electrophoresis in an ABI 377 DNA sequencer
and the results were analyzed by Match Tools and Sequence
Navigator (Applied Biosystems, Foster City, CA, USA).
HLA-A, B serologic typing
Blood samples from all the patients and the control group
were collected in acid citrate dextrose tubes and
Table 1 Demographic and clinical characteristics of pa-
tients with oral squamous cell carcinoma and control group.
Variable Oral cancer Control
(n Z 105) (n Z 190)
Gender
Male 100 121
Female 5 69
Age (y)
Mean  SEM 51.8  0.9 51.3  1.7
Range 30e74 23e80
Location
Buccal mucosa 58 d
Tongue 29 d
Gingiva 12 d
Palate 3 d
Mouth floor 3 d
Stage
I 15 d
II 25 d
III 17 d
IV 48 d
Lymph node metastases
Absent 66 d
Present 39 d
SEM Z standard error of the mean.
HLA typing and OSCC 43transported within 24 hours to the laboratory. Lymphocytes
were isolated using Ficoll-Hypaque (Pharmacia Biotech,
Uppsala, Sweden) gradient centrifugation from 10 mL of
peripheral blood. Antigens were determined by a standard
microlymphocytotoxicity technique in Terasaki Chinese
HLA-ABC 72-well trays (lots 2, 3, 3A, and 3B) and the latest
Terasaki Special Monoclonal Tray-Asian HLA class I (lot 3).
Sequence-specific primed PCR typing
Samples in which serologic typing failed to yield a result
were assayed by the sequence-specific primed PCR typing.
HLA-A and HLA-B typing was done using commercially
available kits (GenoVision, Oslo, Norway). Genomic DNA
was amplified by 24 PCRs for HLA-A and 48 PCRs for HLA-B.
A group of 108 necrokidney donors were also typed for HLA-
C with low resolution using 16 PCRs. Each 10-mL PCR
mixture contained two to four alleles or group-specific
primers and a control primer pair at a lower concentration,
10 PCR buffer (500 mM KCl, 15 mM MgCl2, 100 mM
TriseHCl pH 8.3, 0.01% w/v gelatine), 200 mM each of
deoxyadenosine triphosphate, deoxycytidine triphosphate,
deoxythymidine triphosphate, and deoxyguanosine
triphosphate (Amersham Pharmacia Biotech, Uppsala,
Sweden), cresol red (100 mg/mL), (Sigma, St. Louis, MO,
USA), 5% (v/v) 99.5% glycerol (Fluka, St. Louis, MO, USA),
0.40 mM of the specific primers, and 0.10 mM of the control
primers, 50e100 ng DNA, and 0.40 U of Taq polymerase
(Amersham Pharmacia Biotech).
Statistical analysis
Allele frequencies were determined by direct counting.
Agreement with HardyeWeinberg equilibrium was tested
for genotype frequencies in the controls using PyPop sta-
tistical software12 from the International Histocompatibili-
ty Working Group, based on the method described by Guo
and Thompson.13 The odds ratio (OR) with 95% confidence
intervals (CIs) for each allele family was calculated14e16
and the frequencies of allele families and alleles were
compared between patients with OSCC and healthy con-
trols, as well in subgroups according to age, tumor site,
differentiation, stage, and cervical lymph node metastasis
using the Chi-square test with Yates’ correction and the
Fisher exact test where appropriate. The values of P were
calculated using the Bonferroni inequality method.17 A
value of P < 0.05 (two tailed) was considered statistically
significant. A power calculation was performed based on
the approach of Ohashi et al.18 SPSS 12.0 for Windows (SPSS
Inc., Chicago, IL, USA) was used for statistical analysis.
Results
Demographic data of all participants and clinical charac-
teristics of those with OSCC are shown in Table 1. The al-
leles frequencies for HLA-A, HLA-B, and HLA-DRB1 in study
patients are compared with those of the control group in
Tables 2e4. The frequencies of alleles HLA-A24, HLA-B58,
HLA-DRB1*0405, HLA-DRB1*1201 were significantly higher
in patients with OSCC, while the frequencies of alleles HLA-
B58 and HLA-DRB1*1302 were significantly lower. A numberof haplotype frequencies were either higher or lower in
patients with OSCC than in the control group (Tables 5 and
6). A*1101 and A*2 were the most frequently observed al-
leles in patients with OSCC, although the frequencies did
not differ significantly from those in controls. A*24 was
significantly more common in patients than in controls
(23.3% vs. 16.6%; OR Z 1.53, 95% CI Z 1.00e2.33,
P Z 0.045).
When patients with OSCC were stratified by age, tumor
site, degree of differentiation, or tumor size, we found no
particular association in the distribution of HLA alleles and
haplotypes. However, patients with lymph node metastasis
had higher frequencies of A2/B60, A1101/B62, A2/DR1201,
and DR1101 compared with those without lymph node
involvement. None of the 80 patients with nodal metasta-
ses had the A1101/B60 haplotype, compared with nine of
the 130 without node involvement (Table 7). There were
also several significant differences in haplotype fre-
quencies between patients with early (Stages I and II) and
late (Stages III and IV) stage OSCC (Table 8), including
several that were present in one group or the other but not
in both.
Discussion
In OSCC, Eura et al reported an increased frequency of HLA-
A*2402 in Japan over that in controls (P Z 0.030, relative
risk Z 3.833).10 A similar result in our study was the
significantly higher frequency of HLA-A24 is patients with
OSCC (PZ 0.045, ORZ 1.53, 95% CIZ 1.00e2.33). Tilanus
et al observed significant associations between HLA-B40
antigen and HLA-B*40/DRB1*13 haplotypes in patients
Table 2 Allele frequencies of HLA-A antigens in patients with oral cancer and healthy controls.
Oral cancer (n Z 210) Controls
(n Z 380)
Antigens No. % OR 95% CI P Pc No. %
A1 0 0 ns 1 0.3
A1101 57 27.1 ns 119 31.3
A1102 10 4.8 18 4.7
A2 57 27.1 113 29.7
A24 49 23.3 1.53 1.00e2.33 0.045 63 16.6
A26 11 5.2 10 2.6
A29 0 0 1 0.3
A30 3 1.4 3 0.8
A31 2 1.0 10 2.6
A32 0 0 2 0.5
A33 21 10.0 39 10.3
A68 0 0 1 0.3
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odds ratio.
44 C.-C. Lu et alwith OSCC in the Netherlands.11 Different laboratory
methods and sample size in addition to varying ethnicity
may all contribute to reported variations in the distribution
of HLA types.Table 3 Allele frequencies of HLA-B antigens in patients with o
Oral cancer (n Z 210)
Antigens No. % OR 95%
B13 16 7.6
B15 0 0
B18 0 0
B27 10 4.8
B35 10 4.8
B37 0 0
B38 4 1.9
B39 3 1.4
B44 2 1.0
B46 20 9.5
B48 4 1.9
B51 17 8.1
B52 0 0
B53 0 0
B54 19 9.0 2.42 1.20
B55 4 1.9
B56 1 0.5
B5603 0 0
B58 11 5.2 0.43 0.22
B60 55 26.2
B61 3 1.4
B62 12 5.7
B67 2 1.0
B7 4 1.9
B70 1 0.5
B71 0 0
B75 12 5.7
B76 0 0
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odTraditionally, HLA polymorphisms were typed by sero-
logic responses to HLAs, but this may result in mistyping
about 20% of the time.19,20 As pointed out by Schaffer and
Olerup, this is probably because allelic variations in the HLAral cancer and health controls.
Controls
(n Z 380)
CI P Pc No. %
34 8.9
2 0.5
1 0.3
15 3.9
10 2.6
1 0.3
16 4.2
8 2.1
2 0.5
52 13.7
5 1.3
20 5.3
2 0.5
1 0.3
e4.87 0.010 15 3.9
13 3.4
2 0.5
1 0.3
e0.86 0.014 43 11.3
84 22.1
9 2.4
19 5.0
1 0.3
2 0.5
0 0
1 0.3
20 5.3
1 0.3
ds ratio.
Table 4 Allele frequencies of HLA-DRB1 antigens in patients with oral cancer and healthy controls.
OSCC (n Z 210) Control (nZ 380)
Antigens No. % OR 95% CI P Pc No. %
DRB1*0101 2 1.0 3 0.8
DRB1*0301 10 4.8 31 8.2
DRB1*0401 1 0.5 1 0.3
DRB1*0403 8 3.8 15 3.9
DRB1*0404 1 0.5 4 1.1
DRB1*0405 32 15.2 1.89 1.13e3.18 0.014 33 8.7
DRB1*0406 6 2.9 5 1.3
DRB1*0410 2 1.0 2 0.5
DRB1*0701 3 1.4 5 1.3
DRB1*0802 0 0 3 0.8
DRB1*0803 15 7.1 34 8.9
DRB1*0809 1 0.5 1 0.3
DRB1*0901 23 11.0 59 15.5
DRB1*0903 1 0.5 0 0
DRB1*1001 1 0.5 4 1.1
DRB1*1101 19 9.0 22 5.8
DRB1*1145 1 0.5 0 0
DRB1*1201 16 7.6 2.33 1.10e4.94 0.023 13 3.4
DRB1*1202 23 11.0 36 9.5
DRB1*1301 1 0.5 1 0.3
DRB1*1302 2 1.0 0.25 0.06e1.12 0.039 14 3.7
DRB1*1312 1 0.5 3 0.8
DRB1*1401 3 1.4 15 3.9
DRB1*1403 2 1.0 2 0.5
DRB1*1404 0 0 1 0.3
DRB1*1405 4 1.9 6 1.6
DRB1*1407 0 0 1 0.3
DRB1*1443 0 0 1 0.3
DRB1*1501 15 7.1 33 8.7
DRB1*1502 4 1.9 5 1.3
DRB1*1602 13 6.2 27 7.1
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odds ratio; OSCC Z oral squamous cell carcinoma.
HLA typing and OSCC 45molecule are mainly located in the peptide-binding cleft
and are thus inaccessible to antibodies. Fortunately, ad-
vances in molecular HLA typing methods allow better
definition and characterization of specific HLAs and al-
leles.21 Typing is usually performed either by hybridizing
labeled, sequence-specific oligonucleotide probes to HLA
loci amplified by PCR or using PCR to amplify the HLA DNATable 5 Haplotype frequencies of HLA-A24, HLA-B54, HLA-B58,
in patients with oral cancer and healthy controls.
OSCC (n Z 210)
Antigens No. % OR 95%
A24 49 23.3 1.53 1.00
B54 19 9.0 2.42 1.20
B58 11 5.2 0.43 0.22
DRB1*0405 32 15.2 1.89 1.13
DRB1*1201 16 7.6 2.33 1.10
DRB1*1302 2 1.0 0.25 0.06
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z oddirectly with various primers for extension. We used PCR-
based typing for any samples in which the type could not
be identified serologically.
Previous studies of head and neck cancer have reported
an association between HLA class I expression and tumor
size, degree of differentiation, and the presence and
extent of regional lymph node metastasis.22e26 Of thoseHLA-DRB1*0405, HLA-DRB1*1201, and HLA-DRB1*1302 antigens
Control (nZ 380)
CI P Pc No. %
e2.33 0.045 63 16.6
e4.87 0.010 15 3.9
e0.86 0.014 43 11.3
e3.18 0.014 33 8.7
e4.94 0.023 13 3.4
e1.12 0.039 14 3.7
ds ratio; OSCC Z oral squamous cell carcinoma.
Table 6 Haplotype frequencies of HLA-A/B/DR, HLA-A/B, HLA-A/DR, and HLA-B/DR antigens in patients with oral cancer and
healthy controls.
OSCC (n Z 210) Control
(n Z 380)
Antigens No. % OR 95% CI P Pc No. %
A33/B58/DR1302 1 0.5 0.16 0.02e1.25 0.037 11 2.9
A2/B54/DR0405 3 1.4 12.84 1.43e115.60 0.045 0 0
A24/B51/DR0405 3 1.4 12.84 1.43e115.60 0.045 0 0
A24/B54/DR0403 3 1.4 12.84 1.43e115.60 0.045 0 0
A24/B60/DR1201 4 1.9 16.58 1.92e142.90 0.016 0 0
A24/B62/DR0406 3 1.4 12.84 1.43e115.60 0.045 0 0
A26/B54/DR0405 4 1.9 16.58 1.92e142.90 0.016 0 0
A1101/B60/DR1202 0 0 0.09 0.01e0.73 0.018 9 2.4
A1101/B46 2 1.0 0.23 0.05e1.00 0.028 15 3.9
A24/B62 6 2.9 5.56 1.11e27.79 0.027 2 0.5
A33/B58 10 4.8 0.46 0.23e1.00 0.032 37 9.7
A1101/B7 3 1.4 12.80 1.42e115.29 0.045 0 0
A2/B54 3 1.4 12.84 1.43e115.60 0.045 0 0
A24/B39 3 1.4 12.84 1.43e115.60 0.045 0 0
A26/B54 3 1.4 12.84 1.43e115.60 0.045 0 0
A33/B46 3 1.4 12.84 1.43e115.60 0.045 0 0
A33/B60 3 1.4 12.84 1.43e115.60 0.045 0 0
A24/B61 0 0 0.12 0.01e1.00 0.045 7 1.8
A1101/DR0901 7 3.3 0.43 0.19e1.00 0.047 28 7.4
A1101/DR1202 14 6.7 2.64 1.15e6.06 0.017 10 2.6
A2/DR0803 3 1.4 0.28 0.08e1.00 0.020 19 5.0
A33/DR1302 1 0.5 0.15 0.02e1.14 0.026 12 3.2
A2/DR0405 8 3.8 31.94 4.02e253.91 0.001 0 0
A24/DR0803 8 3.8 31.94 4.02e253.91 0.001 0 0
A24/DR1602 3 1.4 12.84 1.43e115.60 0.045 0 0
A26/DR0405 7 3.3 28.05 3.48e225.81 0.001 0 0
A33/DR1201 4 1.9 16.58 1.92e142.90 0.016 0 0
B58/DR1302 1 0.5 0.16 0.02e1.25 0.037 11 2.9
B60/DR1201 5 2.4 9.24 1.07e79.66 0.024 1 0.3
B27/DR0405 4 1.9 16.58 1.92e142.90 0.016 0 0
B35/DR1201 3 1.4 12.84 1.43e115.60 0.045 0 0
B51/DR0405 4 1.9 16.58 1.92e142.90 0.016 0 0
B54/DR0403 5 2.4 20.37 2.44e170.33 0.006 0 0
B54/DR1405 3 1.4 12.84 1.43e115.60 0.045 0 0
B62/DR1202 3 1.4 12.84 1.43e115.60 0.045 0 0
B75/DR1501 4 1.9 16.58 1.92e142.90 0.016 0 0
B60/DR1401 0 0 0.12 0.01e1.00 0.045 7 1.8
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odds ratio; OSCC Z oral squamous cell carcinoma.
Table 7 Haplotype frequencies of HLA-A/B, HLA-A/DR, and HLA-DR antigens in patients with oral cancer with or without
cervical lymph node metastasis.
Nodal metastasis (n Z 80) No nodal
metastasis
(n Z 130)
Antigens No. % OR 95% CI P Pc No. %
A2/B60 9 11.2 0.19 0.05e0.72 0.010 3 2.6
A1101/B60 0 0 12.88 1.61e102.80 0.011 9 6.9
A1101/B62 4 5.0 0.07 0.01e0.58 0.021 0 0
A2/DR1201 4 5.0 0.07 0.01e0.58 0.021 0 0
DR1101 11 13.8 0.36 0.13e1.00 0.040 7 5.4
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odds ratio.
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Table 8 Haplotype frequencies of HLA-A/B/DR, HLA-A/B, HLA-A/DR, HLA-B/DR, HLA-B38, and HLA-DR0803 antigens in pa-
tients with oral cancer with early (Stages I and II) and late (Stages III and IV) stage disease.
Early stage (n Z 68) Late stage
(n Z 142)
Antigens No. % OR 95% CI P Pc No. %
A1101/B54/DR0405 3 4.4 15.40 1.68e140.84 0.032 0 0
A1101/B60/DR0901 4 5.8 20.15 2.30e176.43 0.010 0 0
A24/B51/DR0405 3 4.4 15.40 1.68e140.84 0.032 0 0
A1101/B60/DR1202 0 0 0.12 0.01e1.00 0.041 8 5.6
A1101/B60 10 14.7 25.00 3.12e200.44 0.0001 1 0.7
A24/B51 6 8.8 13.89 1.63e118.16 0.005 1 0.7
A2/B38 3 4.4 15.40 1.68e140.84 0.032 0 0
A2/B60 0 0 0.07 0.01e0.54 0.005 13 9.1
A24/B54 0 0 0.12 0.01e1.00 0.041 8 5.6
A1101/DR0901 6 8.8 4.56 1.10e18.89 0.033 3 2.3
A24/DR0405 4 5.8 8.93 1.00e81.71 0.038 1 0.7
A1101/DR0403 3 4.4 15.40 1.68e140.84 0.032 0 0
A1101/DR1202 0 0 0.06 0.01e0.50 0.003 14 10.7
B60/DR0901 4 5.8 8.93 1.00e81.71 0.038 1 0.7
B38 3 4.4 15.28 1.67e139.73 0.033 0 0
DR0803 8 11.6 3.08 1.00e9.31 0.041 6 4.6
CI Z confidence interval; HLA Z human leukocyte antigen; OR Z odds ratio.
HLA typing and OSCC 47three variables in our study, only nodal involvement was
associated with differences in haplotype frequency, pa-
tients with nodal metastases having a higher frequency of
A2/B60, A1101/B62, A2/DR1201, and DR1101 and a lower
frequency of A1101/B60. Ogoshi et al reported that HLA-
DR4 and HLA-B52 antigens are associated with lymph node
metastasis in gastric cancer.27 We also found significant
differences in haplotypes between the early and late stages
of the disease. There are varied reasons that affect the
patients’ tumor stages. Cervical node metastasis may be an
important factor in this regard. However, the exact mech-
anism by which these antigens are involved in cervical
lymph node metastasis or how they may impact survival
needs further investigation.
Some of the same HLA alleles we noted in our study
have been reported in association with other cancers. HLA-
A24, more common in our patients with OSCC than in
controls, was identified as a predictor of bilateral breast
cancer in Japanese women.28 The lower frequency of
DRB1*1302 in our patients with OSCC was also noted in
patients with lung cancer.29 These findings raise the pos-
sibility that particular alleles may contribute to or protect
from carcinogenesis. If this theory is borne out by further
investigation, it might eventually lead to specific anti-
cancer immunotherapy.30
There is no question that environmental agents are
involved in the development of OSCC, yet other factors
must be at work as well. Finding specific HLA-type differ-
ences in people with and without OSCC as well as among
those whose OSCC has particular clinical behaviors is the
first step in trying to tease out some of these factors. The
ultimate goal, of course, is to develop better prophylactic,
prognostic, and therapeutic option than we currently have.
Studies such as ours contribute to genetic databases
needed to undergird studies of molecular mechanisms incancer. Amassing such data should help identify targets
that may be amenable to therapeutic manipulation.Conflicts of interest
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